Quick Answer
Nuvectis Pharma, Inc. reported Net Income Loss of -$26.44 million for the year ending 2025.
- Nuvectis Pharma, Inc. showed a decrease of -39.2% in Net Income Loss from 2024 to 2025.
- This data is from Nuvectis Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$23.0 thousand | Q2 2021: -$5.94 million | Q3 2021: -$4.67 million | Q1 2022: -$2.94 million | Q2 2022: -$3.57 million | Q3 2022: -$5.88 million | Q1 2023: -$4.05 million | Q2 2023: -$5.71 million | Q3 2023: -$5.88 million | Q1 2024: -$4.17 million | Q2 2024: -$4.43 million | Q3 2024: -$4.15 million | Q1 2025: -$5.33 million | Q2 2025: -$6.33 million | Q3 2025: -$7.46 million.
- Over the full 5 years of available data (2021 to 2025), Nuvectis Pharma, Inc.'s Net Income Loss has declined by 105.1%.
- Historical annual values: Fiscal year 2025: -$26.44 million | Fiscal year 2024: -$19.00 million | Fiscal year 2023: -$22.26 million | Fiscal year 2022: -$19.09 million | Fiscal year 2021: -$12.89 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: